WallSt Focus
Total 1022 Posts
Exodus Just Bought Grateful—Here’s How It Could Disrupt Stablecoin Payments
Exodus’ acquisition of Grateful adds stablecoin payments, merchant tools, and global expansion potential, helping the company move toward a broader financial superapp despite execution risks.
Avadel Stock Soars As Lundbeck Outbids Alkermes—Will A Bidding War Break Out?
Lundbeck’s higher $23 bid lifts Avadel’s near-term upside and sparks talk of a bidding war, but its non-binding terms, CVR risks, and the board’s support for Alkermes leave the outcome uncertain.
TreeHouse Foods Just Scored A Major Deal—But Is It Worth $2.9 Billion?
Investindustrial’s bid sent TreeHouse Foods soaring as the PE firm targets its margin-expansion plan, private-label growth, strong cash flow, and discounted valuation—despite recent weak results.
Intellia Therapeutics Loses A Patient & $BILLIONS In Value — Can It Recover?
Intellia plunged after a patient died in its ATTR trial, prompting FDA holds on two Phase III studies and raising serious questions about safety, CRISPR risks, and the future of its pipeline.
Nvidia Stock Soars After Blowout Earnings as AI Demand Sends Shockwaves Through Big Tech
Nvidia (NVDA) delivered another blockbuster quarter on Wednesday, igniting a rally across the tech sector and reinforcing its position as the heart of the global AI buildout.
Stock Market Today: Stocks Rise as Nvidia Earnings and Strong Jobs Report Lift Rate-Cut Hopes
US stocks traded higher on Thursday after Nvidia’s solid earnings reignited confidence in the AI trade and newly released jobs data pointed to a sturdy economy, helping renew bets on Federal Reserve rate cuts.
Monro Adopts A Poison Pill After Carl Icahn’s Big Move—What’s Really Going On?
Carl Icahn’s 17% stake in Monro sparked a stock jump and a defensive poison pill, highlighting the company’s fragile turnaround, rising activist pressure, and an uncertain path to unlocking value.